The companion diagnostics market is experiencing significant growth, driven by the rising demand for personalized medicine and targeted therapies. These diagnostic tools enable clinicians to identify the most effective treatments based on a patient’s genetic profile, especially in oncology. Technological advancements, regulatory support, and pharmaceutical partnerships are further accelerating the market. The integration of biomarkers and the growing use of in-vitro diagnostics are key factors fueling expansion. With increased investments in research and the emergence of novel drug-diagnostic co-development models, the market is poised for transformative growth across regions.
See Detailed Insights On:-https://alignstrategicimperative.com/industry/companion-diagnostics-market/
